3rd Aug 2016 08:37
i
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
Verona Pharma plc | ||
2 Reason for the notification (please tick the appropriate box or boxes): | |||
An acquisition or disposal of voting rights |
√ | ||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||
An event changing the breakdown of voting rights | |||
Other (please specify): | |||
3. Full name of person(s) subject to the notification obligation: iii |
Vivo Ventures VII, LLC | ||
4. Full name of shareholder(s) (if different from 3.):iv |
Vivo Ventures fund VII, LP Vivo Ventures VII Affiliates Fund, LP | ||
5. Date of the transaction and date on which the threshold is crossed or reached: v |
July 29, 2016 | ||
6. Date on which issuer notified: |
July 29, 2016 | ||
7. Threshold(s) that is/are crossed or reached: vi, vii |
6.5% to 9.84% Change at Combined Interest Level | ||
8. Notified details: | |||||||
A: Voting rights attached to shares viii, ix | |||||||
Class/type of shares
if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||
Direct | Direct xi |
Indirect xii |
Direct |
Indirect | |||
GB00B06GSH43 |
65,600,000 |
65,600,000 |
252,393,874 |
252,393,874 |
9.84% | ||
B: Qualifying Financial Instruments | ||||
Resulting situation after the triggering transaction | ||||
Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights |
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | |
Nominal |
Delta | |||||
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
252,393,874 |
9.84% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Vivo Ventures VII, LLC is the general partner of both Vivo Ventures Fund VII, LP (VV Fund VII) and Vivo Ventures VII Affiliates Fund, LP. (Affiliates Fund VII). Accordingly, Vivo Ventures VII, LLC may be deemed to have indirect beneficial ownership of shares of the Issuer directly owned by VV Fund VII and Affiliates Fund VII. As of the date of this filing, VV Fund VII and Affiliates Fund VII beneficially own 247,010,316 and 5,383,558 shares of Common Stock respectively.
Proxy Voting: | |
10. Name of the proxy holder: | |
11. Number of voting rights proxy holder will cease to hold: | |
12. Date on which proxy holder will cease to hold voting rights: | |
13. Additional information: | |
14. Contact name: | Vivo Capital, LLC Attn: Cinthia Sheu |
15. Contact telephone number: |
+1-650-688-0818 |
Related Shares:
VRP.L